Paris, 23 may 2017, 18 hours – OSE Immunotherapeutics AG (ISIN: FR0012127173; Mnémo: OSE), announced the online release of preparatory documents for the combined general Meeting to be held on June 14, 2017 at 9: 30 am at the Hotel Pershing, 49, rue Pierre Charron, 75008 Paris.
Download the free guide
Boost your gains
The notice of meeting, being worth convening notice including the agenda and the draft resolutions was published in the BALO of the may 5, 2017.
The preparatory documents for the Assembly set out in article R. 225-73-1 of the French commercial Code are online on the website of the company (http://ose-immuno.com/documentation/assemblee-generale/).
The preparatory documents for the Assembly will also be kept at the disposal of shareholders as of the convening of the Meeting. In accordance with the applicable regulatory provisions :
Any registered shareholder may, until the fifth day inclusive before the Meeting, request the company to send him the documents referred to in articles R. 225-81 and R. 225-83 of the French commercial code, if applicable, at its request, by electronic means. For holders of bearer shares, the exercise of this right is subject to the provision of a certificate of attendance in the bearer securities accounts held by the authorized intermediary ;
All shareholders may take cognizance at the registered office of the company of the documents referred to in articles L. 225-115 and R. 225-83 of the French commercial code (22 Boulevard Benoni Goullin 44200 Nantes).
ABOUT DARE IMMUNOTHERAPEUTICS
Our ambition is to become one of the world leaders in immunotherapy activation and regulation
DARE Immunotherapeutics) is a biotechnology company specializing in the activation and immune regulation in immuno-oncology, autoimmune diseases and in transplantation.
The company has a balanced portfolio, with a risk profile that is diverse, ranging from the clinical phase to registration of R&D :
Immuno-oncology :
??? Tedopi®, a combination of 10 néoépitopes optimized to induce an activation response in immuno-oncology – ongoing Phase 3 registration in the lung cancer advanced in Europe and the United States, in patients with HLA-A2+ – Status orphan to the United States, Registration as provided for in 2019 – A Phase 2 study of Tedopi® in combination with a checkpoint inhibitor in NSCLC is planned in 2017.
??? DARE-172 (Effi-DEM), checkpoint of the new generation targeting cells of the myeloid suppressor via receptor SIRP-? – In preclinical in several cancer models.
In autoimmune diseases and transplantation :
??? FR104, immunotherapy antagonist of the CD28 – Results of Phase 1 positive – refers to autoimmune diseases, and transplantation – Licensed to Janssen Biotech Inc. for further clinical development.
??? DARE-127 (Effi-7), immunomodulatory receptor antagonist to interleukin-7 – preclinical in inflammatory bowel disease and other autoimmune diseases – Option license agreement with Servier for the development and commercialization of the product.
In the light of medical needs targeted, these products have a real potential blockbuster and make the company the ability to enter into global agreements at different stages of their development with major pharmaceutical players.
DARE Immunotherapeutics seeks the field of immunotherapy, a very attractive market in full expansion. The immunotherapy of cancer may represent to the year 2023, nearly 60% of treatments, compared to less than 3% at the present time* and the market is estimated is estimated to be $ 67 billion by 2018**.
There are more than 80 autoimmune diseases that represent an important market integrating of the major players in the pharmaceutical industry, with sales in excess of 10 billion euros for the main products. The medical need is still largely unfulfilled and will require the provision of new products to control the immune system’s innovative and responsive.
*Citi Research Equity
**BCC Research
More information on http://ose-immuno.com
Download the free guide
Boost your gains
